Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3163 - Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): time to maximum response and optimal treatment duration.

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Neuroendocrine Tumours

Presenters

Angela Lamarca

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

A. Lamarca1, J. Barriuso2, L. McCallum1, G. Papaxoinis1, M. Nasralla1, C. Nuttall1, M. Frizziero1, Z. Kordatou1, M.G. McNamara2, R.A. Hubner1, P. Manoharan3, W. Mansoor1, J.W. Valle4

Author affiliations

  • 1 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 2 Medical Oncology, The University of Manchester / The Christie, M204BX - Manchester/GB
  • 3 Radiology / Nuclear Medicine, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 4 Medical Oncology, The University of Manchester / The Christie, Manchester/GB
More

Resources

Abstract 3163

Background

TemCap is an option for treatment of NENs; benefit of treatment until progression rather than a fixed 6-month (mo) course remains unclear.

Methods

Patients (pts) diagnosed with advanced NEN (pathology-confirmed), treated with TemCap with follow-up and available radiological response data were eligible for this retrospective study. Efficacy was assessed by RECIST v1.1.

Results

Of 62 pts identified (Jan’12-Jan’17), 60 were eligible. Median (med) age at starting TemCap was 63.6 yrs; 50% were male; Performance Status (PS) 0-1 (83.3%), 2 (16.7%); with NEN of lung (33.3%), pancreas (21.7%), small bowel (16.7%), colorectal (3.3%) and other (25.0%) origin. The med Ki-67 was 12% (range 1-29); most (83.3%) were well-differentiated [grade (G)1/typical (18.3%); G2/atypical (65%); G3 (16.7%)], non-functional (75.0%) and metastatic (90.0%). Pts received TemCap as first- (33.3%) or second- (35.0%) line, for a med of 5.58 mo (95%CI 5.33-5.78). After 6 cycles, 38 pts (63.3%) were progression-free (i.e. eligible for maintenance TemCap [mTemCap]); 11 received mTemCap, 27 did not. Rationale for mTemCap was good response (n = 7), good tolerance (n = 3) or pts’ wishes (n = 1). Overall, 29 pts (48.3%) had stable disease and 14 pts (23.3%) achieved a partial response (PR); med reduction in responding pts was -56.7% (95%CI -76.4 to -33.3); 4 additional pts (6.67%) achieved a reduction >20% but

Conclusions

Achieving a PR impacts on PFS in pts treated with TemCap. Although PR is an early event, maximum response is not achieved until later in pts’ treatment/follow-up; mTemCap until progression is appropriate for pts who are progression-free at 6 mo and have good tolerance to treatment.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.